Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 18/20 | 0.71 |
| ▸ | ERBB4 | Q15303 | 8/20 | 0.50 |
| ▸ | ERBB3 | P21860 | 7/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | CSK | P41240 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484335 | 0.88 | EGFR (0.80) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL3485017 | 0.83 | EGFR (0.70) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL13070280 | 0.83 | EGFR (0.70) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL3484597 | 0.83 | EGFR (1.00) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL3485034 | 0.83 | EGFR (0.69) | EGFRERBB2ERBB4ERBB3 | |
| Hydrochloric Acid SCHEMBL3484214 | 0.82 | EGFR (0.84) | EGFRERBB2ERBB4ERBB3LCK | |
| Hydrochloric Acid SCHEMBL3401799 | 0.82 | EGFR (0.69) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL3484683 | 0.82 | EGFR (0.51) | EGFRERBB2ERBB4ERBB3 | |
| SCHEMBL3483967 | 0.82 | EGFR (0.70) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL13679445 | 0.81 | EGFR (0.49) | EGFRERBB2ERBB4ERBB3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | EGFR 13/4885ERBB2 1/4885ERBB4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.